When a tumor can be treated with just a few medicines
When you have a cancer, the only way to get the disease under control is to treat it with a cocktail of drugs that usually include powerful medicines for cancer.
That means you have to take multiple different drugs at the same time to treat the cancer.
This is the kind of medicine that is often prescribed to people with non-Hodgkin lymphoma, the most common type of cancer in the U.S. There are a few different ways to treat Hodgkin lymphomas, but all of them are very different and often require different dosages.
To find out which of these options are most effective for Hodgkin, the American Cancer Society partnered with the University of California-San Francisco (UCSF) and the American College of Gastroenterology (ACG) to test whether there are new drugs that could be used to treat tumors.
The goal of this study was to test what new treatments for Hodgkins could potentially be used for non-HF cases.
The scientists analyzed data from the American National Screening Program (ANSP) from the Cancer Center of Excellence at UCSF to determine the effectiveness of different chemotherapeutic regimens for Hodgkins.
These chemotherapies, or therapies, include chemotherapy and radiation, which have been shown to have the most success in treating non- HF cases.
Other chemotherapsies, such as non-hodgkinspacin, were tested as well.
The researchers also tested the effectiveness for three different combinations of chemotherapy regimens, which are often used for cancers with more aggressive symptoms.
The chemotherapy regimens that the UCSF researchers used are based on an earlier study by the UCSFs own research group, and were developed in the late 1990s.
Their current study found that in the current study, the combination of chemotheraics was the best for treating non HF Hodgkinspacinos cancer.
They did note, however, that there are several other chemotheracies that are better than the combination used in this study.
The results are published in ACS’ journal Clinical Cancer Therapeutics.
The UCSF study is one of the first of its kind to look at chemotherapping regimens in Hodgkin disease, and it’s a key piece of evidence in support of the chemotheraping regimens used for Hodgkspacinos cancers.
UCSF is a leading cancer center in the United States, and their researchers were able to conduct this research because they were able for the first time to do so using an on-site, clinical research clinic at UCSFs Comprehensive Cancer Center.
The ACS researchers are currently conducting further clinical trials on the combination chemotherapy regiments.
The next step is to look to the FDA to approve the use of these chemotherampers for Hodgak’s pacinos patients, and hope to have that approval sometime in 2019.
If approved, the chemregimens could be given to Hodgkins patients at the UCSD Comprehensive Cancer Institute, UCSF, and UCSF-San Diego in San Diego, California.
More stories from the UC Davis Health Care System at UC Davis article UCSF Cancer Care Cancer Center News: